Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

Abstract

Nivolumab demonstrated antitumor activity with a manageable safety profile across the three doses studied in mRCC. No dose-response relationship was detected as measured by PFS. These efficacy and safety results in mRCC support study in the phase III setting.